A neuroendocrine tumor in a neck node that stains for calcitonin
From the pathology comment to the diagnosis
The scan reads "thymic" or "mediastinal" because that is where the node is, not where the tumor started.A medullary carcinoma that presents as a mediastinal mass with a small calcified thyroid nodule is still a thyroid cancer, and the thyroid is still the primary to examine, image and, if the disease is confined to the neck, resect.
RET, the families, and why the adrenal comes first
The receptor, drawn
Risk by codon, and when the carrier's thyroid comes out
| ATA risk | RET mutation | Prophylactic thyroidectomy |
|---|---|---|
| Highest | M918T (MEN2B) | In the first year of life |
| High | Codon 634, A883F | At or before age 5; earlier if calcitonin rises |
| Moderate | 609, 611, 618, 620, 630, 768, 790, 804, 891 and others | When calcitonin rises; annual calcitonin and ultrasound from age 5 |
Calcitonin, not the codon alone, times the operation in carriers.Node metastases are unlikely below 40 pg/mL. The codon sets the ceiling of risk; the calcitonin tells you where the patient is under it (Wells 2015).
Before any scalpel
Pheo first. Always. In both syndromes, before every operation.
Calcitonin and CEA as the clock of the disease
Doubling time against survival
| Calcitonin doubling time | 5-year survival | 10-year survival |
|---|---|---|
| Under 6 months | 25% | 8% |
| 6 to 24 months | 92% | 37% |
| Over 24 months | 100% | 100% |
Four values over time, calcitonin and CEA both; the ATA website has the calculator.Barbet 2005, 65 patients; confirmed in the meta-analysis of Meijer 2010 (doubling time under 1 year against over 1 year). In the meta-analysis the CEA doubling time predicted even better than the calcitonin one. Discordance, CEA climbing while calcitonin stalls, means a tumor losing calcitonin and keeping CEA: dedifferentiation, and the worse of the two clocks is the one to believe.
What the number tells you where
Over 20: central and ipsilateral lateral neck.
Over 50: contralateral central.
Over 200: contralateral lateral.
Over 500: upper mediastinum (Machens 2010; with current assays the thresholds are higher, 242 pg/mL for the central neck, Du 2025).
150 or more: CT or MRI of neck, chest and liver, bone scan and MRI of spine and pelvis.
Recurrence imaging: F-DOPA PET is the most accurate; DOTATATE PET for bone and for lutetium candidates; an FDG-avid tumor is a fast one: avidity tracks short doubling time and poor survival. Neither PET is for initial staging.
Rising markers alone never start systemic therapy.Treatment is for structural progression by RECIST or for symptoms. A calcitonin in the thousands with stable scans and a doubling time of 3 years is watched, not treated (Wells 2015; NCCN 2026).
Three things the C cell does not do
Unresectable or metastatic: what cannot be cut
The algorithm
Decide in clinic
The ultrasound, the metanephrines and the RET result: three tests before the first prescription.
Mnemonics, and the questions you will be asked
Eight to carry
Questions
Sources
Retrieved from PubMed, read on Oct 20, 2026.
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015. doi:10.1089/thy.2014.0335
- Hadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer (LIBRETTO-531). N Engl J Med 2023. doi:10.1056/NEJMoa2309719
- Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer (EXAM). J Clin Oncol 2013. doi:10.1200/JCO.2012.48.4659
- Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 2017. doi:10.1093/annonc/mdx479
- Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer (ZETA). J Clin Oncol 2012. doi:10.1200/JCO.2011.35.5040
- Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005. doi:10.1210/jc.2005-0044
- Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf) 2010. doi:10.1111/j.1365-2265.2009.03666.x
- Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010. doi:10.1210/jc.2009-2368
- Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007. doi:10.1210/jc.2006-1590
- Xu B, Fuchs TL, Ahmadi S, et al. International Medullary Thyroid Carcinoma Grading System: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 2022. doi:10.1200/JCO.21.01329
- Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008. doi:10.1210/jc.2007-1714
- Giovanella L, Treglia G, Iakovou I, et al. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2020. doi:10.1007/s00259-019-04458-6
- Saba NF, Ismaila N, Adkins D, et al. Systemic treatment of thyroid cancer: ASCO guideline. J Clin Oncol 2026. doi:10.1200/JCO-26-00235
- Du Y, Shen C, Song K, et al. Updated thresholds of basal calcitonin level and extent of lymph node metastasis in initially treated medullary thyroid cancer. JAMA Otolaryngol Head Neck Surg 2025. doi:10.1001/jamaoto.2025.0542
- Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 1998. doi:10.1046/j.1365-2265.1998.00392.x
- Trimboli P, Mian C, Piccardo A, Treglia G. Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine 2022. doi:10.1007/s12020-021-02892-x
- Kim J, et al. Serum carcinoembryonic antigen as a biomarker for medullary thyroid carcinoma. Int J Thyroidol 2021. doi:10.11106/ijt.2021.14.1.59
- Llewellyn D, et al. Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review. Endocr Connect 2021. doi:10.1530/EC-21-0170
- Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007. doi:10.1210/jc.2007-1005
- Rowell NP. The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: a systematic review. Radiother Oncol 2019. doi:10.1016/j.radonc.2019.03.033
- Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol 2020. doi:10.1016/j.jtho.2020.01.006
- Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 2020. doi:10.1016/j.annonc.2020.09.015
- Verbeek HH, Plukker JT, Koopmans KP, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 2012. doi:10.2967/jnumed.112.105940